Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1985]
News [3223]
Articles [134]
Editorials [3]
Conferences [121]
elearning [18]
ASH 2023: New drug helps narrow racial survival disparity in patients with acute myeloid leukaemia
ASH 2023: New drug helps narrow racial survival disparity in patients with acute myeloid leukaemia
ASH 2023: Venetoclax with standard chemo-immunotherapy induced a high response rate as first-line treatment for mantle cell lymphoma and was generally well tolerated
ASH 2023: Venetoclax with standard chemo-immunotherapy induced a high response rate as first-line treatment for...
ASH 2023: Combination immunotherapy produces high response rate in early results of trial targeting high-risk follicular lymphoma
ASH 2023: Combination immunotherapy produces high response rate in early results of trial targeting high-risk...
ASH 2023: Third-generation anti-CD19 CAR T-cells demonstrate efficacy without neurotoxicity in B-cell lymphoma phase 1 clinical trial
ASH 2023: Third-generation anti-CD19 CAR T-cells demonstrate efficacy without neurotoxicity in B-cell lymphoma...
ASH 2023: Patients with a common form of acute myeloid leukaemia report better quality of life when treatment includes new drug quizartinib
ASH 2023: Patients with a common form of acute myeloid leukaemia report better quality of life when treatment...
FDA grants accelerated approval to pirtobrutinib for chronic lymphocytic leukaemia and small lymphocytic lymphoma
FDA grants accelerated approval to pirtobrutinib for chronic lymphocytic leukaemia and small lymphocytic lymphoma
ASH 2023: Cell therapy appears safe and effective for lymphoma in remission
ASH 2023: Cell therapy appears safe and effective for lymphoma in remission
ASH 2023: Study provides insight into underlying gene mutations in myelodysplastic syndromes
ASH 2023: Study provides insight into underlying gene mutations in myelodysplastic syndromes
ASH 2023: Pilot study uses circulating tumour DNA to reliably predict relapse in patients with diffuse large B-cell lymphoma
ASH 2023: Pilot study uses circulating tumour DNA to reliably predict relapse in patients with diffuse large B...
ASH 2023: Bispecific antibody drives myeloma precursor condition to undetectable levels in phase II trial
ASH 2023: Bispecific antibody drives myeloma precursor condition to undetectable levels in phase II trial

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation